New treatment to remove harmful cholesterol particles from the blood
Therapeutic Approach to Clear sdLDL from Circulation
This study is looking at a new way to help people with heart disease by finding a method to remove harmful small particles in the blood that can still be risky, even when overall cholesterol levels are low, and it focuses on how these particles interact with the liver to improve health outcomes.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Imetabolic Biopharma Corporation NIH-funded |
| Lab location | 1 site (Tempe, United States) |
| Project ID | NIH-10920333 on NIH RePORTER |
What this research studies
This research focuses on developing a novel therapeutic approach to clear small dense low-density lipoprotein (sdLDL) particles from circulation, which are linked to increased cardiovascular disease risk. The study aims to understand how these particles, despite lowering overall LDL cholesterol levels, continue to pose a threat due to their composition and metabolic behavior. By targeting the excess Apolipoprotein C-III present on sdLDL, the researchers hope to enhance the clearance of these harmful particles from the bloodstream, potentially improving patient outcomes. The methodology involves exploring the interactions between sdLDL and liver receptors to find effective ways to reduce their levels in patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with elevated levels of small dense LDL cholesterol and a history of cardiovascular disease.
Not a fit: Patients who have normal cholesterol levels and no cardiovascular disease risk factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly lower cardiovascular disease risk for patients by effectively removing harmful cholesterol particles from their blood.
How similar studies have performed: While the approach to target sdLDL is innovative, similar strategies targeting cholesterol metabolism have shown promise in other studies.
Where this research is happening
Tempe, United States
- Imetabolic Biopharma Corporation — Tempe, United States (Active)
Researchers
- Principal investigator: Kiernan, Urban a — Imetabolic Biopharma Corporation
- Study coordinator: Kiernan, Urban a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.